Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Z F Xu

Showing results (81-90 of 131) with videos related to

Pageof 14
Sort By:
Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi|December 20, 2019
[Analysis of clinical characteristics, treatment response rate and survival of 77 myelodysplastic syndrome patients with del (5q) syndrome]D Liu, Z F Xu, T J Qin, et al.
Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi|April 11, 2024
[Efficacy and safety analysis of venetoclax combined with hypomethylating agents for the treatment of higher-risk myelodysplastic syndromes in the real world]Q Y Gao, B Li, S Q Qu, et al.
Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi|June 25, 2023
[Clinical characteristics and prognostic factors of patients with Philadelphia-negative myeloproliferative neoplasm accelerated/blast phase]X Yan, T J Qin, B Li, et al.
Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi|February 2, 2019
[Ruxolitinib combined with prednisone, thalidomide and danazol for treatment of myelofibrosis: a pilot study]Z F Xu, T J Qin, H L Zhang, et al.
Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi|February 9, 2026
[External validation and incremental value assessment of the RR6 prognostic model in Chinese myelofibrosis patients treated with ruxolitinib: focusing on overall survival]N N Liu, B Li, T J Qin, et al.
Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi|August 17, 2017
[The efficacy and safety of the patients of myelodysplastic syndromes-refractory anemia with excess blasts treated with decitabine alone or CAG/HAG regimen]Z F Xu, T J Qin, H L Zhang, et al.
Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi|December 21, 2016
[A pilot study of ten-day decitabine regimen as initial therapy for newly diagnosed elderly patients with acute myeloid leukemia]T J Qin, Z F Xu, Y Zhang, et al.
Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi|October 28, 2020
[Molecular features and prognostic value of RAS mutations in patients with myelodysplastic syndromes]H J Huang, B Li, T J Qin, et al.
The British Journal of Radiology|September 3, 2009
Imaging features of hepatic angiomyolipomas on real-time contrast-enhanced ultrasoundZ Wang, H-X Xu, X-Y Xie, et al.
International Journal of Laboratory Hematology|December 24, 2015
Identification of RUNX1 gene breakage and copy number variation in acute myeloid leukemiaL Li, X L Qi, X H Chen, et al.
Pageof 14

Showing results (81-90 of 131) with videos related to

Sort By:
Pageof 14
Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi|December 20, 2019
[Analysis of clinical characteristics, treatment response rate and survival of 77 myelodysplastic syndrome patients with del (5q) syndrome]D Liu, Z F Xu, T J Qin, et al.
Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi|April 11, 2024
[Efficacy and safety analysis of venetoclax combined with hypomethylating agents for the treatment of higher-risk myelodysplastic syndromes in the real world]Q Y Gao, B Li, S Q Qu, et al.
Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi|June 25, 2023
[Clinical characteristics and prognostic factors of patients with Philadelphia-negative myeloproliferative neoplasm accelerated/blast phase]X Yan, T J Qin, B Li, et al.
Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi|February 2, 2019
[Ruxolitinib combined with prednisone, thalidomide and danazol for treatment of myelofibrosis: a pilot study]Z F Xu, T J Qin, H L Zhang, et al.
Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi|February 9, 2026
[External validation and incremental value assessment of the RR6 prognostic model in Chinese myelofibrosis patients treated with ruxolitinib: focusing on overall survival]N N Liu, B Li, T J Qin, et al.
Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi|August 17, 2017
[The efficacy and safety of the patients of myelodysplastic syndromes-refractory anemia with excess blasts treated with decitabine alone or CAG/HAG regimen]Z F Xu, T J Qin, H L Zhang, et al.
Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi|December 21, 2016
[A pilot study of ten-day decitabine regimen as initial therapy for newly diagnosed elderly patients with acute myeloid leukemia]T J Qin, Z F Xu, Y Zhang, et al.
Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi|October 28, 2020
[Molecular features and prognostic value of RAS mutations in patients with myelodysplastic syndromes]H J Huang, B Li, T J Qin, et al.
The British Journal of Radiology|September 3, 2009
Imaging features of hepatic angiomyolipomas on real-time contrast-enhanced ultrasoundZ Wang, H-X Xu, X-Y Xie, et al.
International Journal of Laboratory Hematology|December 24, 2015
Identification of RUNX1 gene breakage and copy number variation in acute myeloid leukemiaL Li, X L Qi, X H Chen, et al.
Pageof 14